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For more than 50 million American women, and millionsof women in other countries who are over the age of 50
years, the decision whether or not to use estrogen replacement
therapy (ERT) for chronic disease prevention is often a
difficult one. Established benefits of treatment for meno-
pausal symptoms and prevention of osteoporosis must be
weighed against documented risks of therapy, including
venous thromboembolic events (VTE), gallbladder disease,
and a possible increased risk of breast cancer. Unopposed
ERT is also associated with an increased risk of endometrial
cancer in women with a uterus. Therefore, it is typically
combined with a progestin and is referred to as hormone
replacement therapy (HRT). The impact of ERT/HRT on
cardiovascular disease (CVD) is of great public health im-
portance, because CVD is the leading cause of death and a
major contributor to disability in women.1 The purpose of this
advisory is to summarize the currently available data con-
cerning potential CVD benefits and risks associated with
ERT/HRT and to provide updated clinical recommendations
regarding its use in the secondary and primary prevention
of CVD.
Biological Basis for a Role of ERT in CVD
Mendelsohn and Karas2 recently reviewed the physiological
effects of estrogen on the cardiovascular system. Briefly,
cardiovascular cells, as well as reproductive tissues, bone,
liver, and brain, express both of the known estrogen recep-
tors, estrogen receptor-a (ER-a) and estrogen receptor-b
(ER-b). These receptors are important targets for endogenous
estrogen, ERT, and pharmacological estrogen agonists. Es-
trogen–estrogen receptor complexes serve as transcription
factors that promote gene expression with a wide range of
vascular effects, including regulation of vasomotor tone and
response to injury, that may be protective against develop-
ment of atherosclerosis and ischemic diseases. Estrogen
receptors in other tissues, such as the liver, may mediate both
beneficial effects (eg, changes in apoprotein gene expression
that improve lipid profiles) and adverse effects (eg, increases
in gene expression of coagulation proteins and/or decreases in
fibrinolytic proteins). Two general estrogen-mediated vascu-
lar effects are recognized. Rapid, transient vasodilation oc-
curs within a few minutes after estrogen exposure, indepen-
dently of changes in gene expression.2 This rapid vasodilation
appears to be due to the novel ER-a–mediated activation of
the endothelial nitric oxide synthase enzyme, but it is of
unclear physiological significance. Longer-term effects
of estrogen on the vasculature, such as those related to
limiting the development of atherosclerotic lesions or vascu-
lar injury, occur over hours to days after estrogen treatment
and have as their hallmark alterations in vascular gene
expression. Progesterone and other hormonal receptors are
also expressed in the vasculature, although their role in the
development of CVD is poorly defined. At present, the sum
clinical impact of the genomic and nongenomic effects of
ERT/HRT is uncertain. As the molecular mechanisms respon-
sible for the effects of estrogen are further elucidated,
therapies may evolve that optimize the benefits of estrogen
therapy while minimizing the risks.
In addition to potentially beneficial vascular effects of
ERT, well-established lipid alterations associated with oral
ERT include favorable reductions in low-density lipoprotein
(LDL) cholesterol and lipoprotein(a) and increases in high-
density lipoprotein (HDL) cholesterol.3,4 When ERT is com-
bined with medroxyprogesterone acetate (MPA), there is
attenuation of the beneficial HDL-raising effect. This atten-
uation is decreased when ERT is combined with natural
progesterone.3 Oral ERT increases triglyceride levels ’20%,
although the clinical significance of this has not been
established.3
The effects of ERT/HRT on several more recently recog-
nized risk markers for CVD have been reviewed.5 Fibrinogen,
plasma viscosity, plasminogen activator inhibitor-1, tissue
plasminogen activator, insulin sensitivity, homocysteine, and
markers of platelet aggregation and endothelial cell activation
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are favorably affected by estrogen therapy. Moreover, estro-
gen inhibits intimal hyperplasia and smooth muscle migra-
tion, promotes angiogenesis, and has antioxidant properties.
However, HRT increases C-reactive protein levels, which
suggests a possible proinflammatory effect.6 Increases in
factor VII, prothrombin fragments 1 and 2, and activated
protein C resistance and a decrease in antithrombin III are
also seen.5 Although these effects might adversely affect the
development of CVD, the clinical relevance of the impact of
HRT on these markers is not known. In general, the majority
of surrogate end-point data support a positive role of ERT/
HRT in the prevention of CVD, although enhanced CVD risk
is also biologically plausible.
Should HRT Be Used in Women With
Established CVD?
The Heart and Estrogen/progestin Replacement Study
(HERS) was specifically designed to test the hypothesis that
treatment with conjugated equine estrogen (CEE) 0.625 mg/d
plus MPA 2.5 mg/d would reduce the combined incidence of
nonfatal myocardial infarction (MI) and coronary heart dis-
ease (CHD) death compared with placebo in women with
prior history of MI, coronary revascularization, or angio-
graphic evidence of CHD.7 This was the first large-scale
randomized clinical-outcome trial of HRT for prevention of
CHD in postmenopausal women. After an average of 4.1
years of follow-up, there was no difference in the primary
outcome of nonfatal MI and coronary death between the
hormone and placebo arms. A post hoc time-trend analysis
revealed a significant 52% increase in cardiovascular events
(42.5/1000 person-years versus 28.0/1000 person-years) in
the first year in the HRT group compared with placebo, with
a nonsignificant trend toward fewer events in the treatment
arm compared with placebo in later years (23.0/1000 person-
years versus 34.4/1000 person-years).
Numerous explanations have been proposed for the overall
null effect of HRT in HERS. These include inadequate
duration of follow-up, adverse effects of MPA, bidirectional
effects of estrogen (early risk and late benefit), a population
of women too old to benefit from therapy (average age was
66.7 years), a preparation of HRT that was not ideal, chance,
or that HRT is ineffective in preventing recurrent cardiovas-
cular events in women with established disease.8 A long-term
follow-up of the HERS cohort may provide additional infor-
mation about the role of HRT in secondary prevention.
The Estrogen Replacement and Atherosclerosis (ERA)
Trial, the first randomized angiographic end-point trial to test
the effect of ERT and HRT on the progression of atheroscle-
rosis in postmenopausal women with documented coronary
stenosis, showed no benefit of CEE 0.625 mg/d combined
with MPA 2.5 mg/d on angiographic progression of disease,
lending support to the HERS findings.9 The ERA Trial also
included an estrogen-only arm that showed no angiographic
benefit compared with placebo, which suggests that the null
result of HRT was not due to adverse effects of MPA. The
generalizability of these findings has been questioned be-
cause of the relevance of angiographic end points, the drug
regimen, the older age of the participants (mean of 65.8
years), and the length of time since menopause before
ERT/HRT was instituted (mean of 23.1 years).10 Although
previous observational studies using angiographic end points
showed a consistent inverse association between ERT/HRT
use and the extent of coronary atherosclerosis, these studies
were not prospective and randomized in design.11 The dis-
cordance between these findings and the ERA results could
be due to differences in populations, drug regimens, duration
of therapy, extent of CHD, levels of cholesterol, and other
preventive care. Alternatively, nonrandomized studies may
have overestimated a benefit of HRT due to a “healthy-user”
effect in women who receive such therapy. Ongoing prospec-
tive angiographic studies (Table) will provide additional data
regarding the effect of HRT on the progression of coronary
disease. Recently, a single-center trial of postmenopausal
women with increased intimal-medial thickness showed that
48 weeks of treatment with 17-b estradiol (with or without
gestodene) had no effect on the progression of carotid
intimal-medial thickness despite significant beneficial effects
on LDL cholesterol and fibrinogen.12
These data suggest no overall cardiovascular benefit and a
possible early increased risk of CVD events when HRT is
initiated in women with documented atherosclerosis. Several
limitations inherent in the conduct and analysis of clinical
trials affect the interpretation of these results. Examples
include the relatively short duration of treatment, nonadher-
ence with study medication (more women discontinued HRT
than placebo in HERS, but the data were analyzed by
intention to treat), and the fact that the results may not be
generalizable to different HRT formulations or populations
that differ from the study participants. Follow-up data from
HERS are awaited to assess any potential for a longer-term
effect of HRT in secondary prevention of CHD.
It has been suggested that the results of completed second-
ary prevention trials may not be applicable to younger
women; however, it is less common for cardiovascular events
to occur before women are in their 60s. Also, it is possible
that ERT/HRT regimens other than those tested, such as
lower doses of ERT, different preparations of estrogen or
progestin, or different routes of delivery, might be beneficial
for secondary prevention of CHD. Lastly, it has been hypoth-
esized that if women were given HRT early after menopause,
it might be possible to prevent the development of CHD more
easily than to prevent its progression once established.
Ongoing Studies of HRT and CHD
Angiographic End-Point Trials
c Estrogen and Bypass Graft Atherosclerosis Regression Trial (EAGER)
c Women’s Lipid Lowering Heart Atherosclerosis Trial (WELLHART)
c Women’s Atherosclerosis Vitamin/Estrogen Trial (WAVE)
Primary prevention
c Women’s Health Initiative (WHI)
c Women’s International Study of long Duration Oestrogen after
Menopause (WISDOM)
Secondary prevention
c HERS Follow-up Study
c EStrogen in the Prevention of ReInfarction Trial (ESPRIT)
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Unfortunately, no controlled data are available that address
the timing of initiation of therapy on rates of CVD.
Should HRT Be Used for Primary Prevention
of CHD?
Results are not yet available from ongoing large-scale con-
trolled trials of ERT/HRT for primary prevention. Therefore,
the quality of data available to guide decisions regarding
HRT use for primary prevention is less than that available for
secondary prevention. The majority of observational epide-
miological studies that examined the role of ERT/HRT in
women without established CHD have consistently demon-
strated a lower incidence of CHD events among users versus
nonusers. A recent meta-analysis showed an approximate
35% reduction in CHD events among users of ERT alone,
with similar results observed for HRT.13 The consistency of
the data and the magnitude of benefit observed in these
studies lend support to a role of HRT in the primary
prevention of CHD; however, bias cannot be ruled out.
Although epidemiological studies have the advantage of
examining the effect of therapy over a longer duration of time
than is typical of a randomized clinical trial, several forms of
bias inherent in observational designs have been reviewed
recently.14 Women who are prescribed HRT are often health-
ier than nonusers (selection bias). Monitoring and treatment
may be more intensive for women taking HRT (prevention
bias). Adherence to taking a medication on a regular basis
(even if it is a placebo) is associated with significant survival
benefit (compliance bias). HRT may be stopped because of
illness, leading to misclassification as a nonuser, artificially
reducing the risk among women categorized as users (survi-
vor bias). Finally, early adverse effects of HRT may not be
observed if susceptible women have died and are not part of
the cohort (prevalence-incidence bias).
Randomized controlled trials are designed to overcome
many of these types of bias. Ongoing trials (Table) may soon
provide additional data to help guide recommendations re-
garding the use of HRT for primary prevention of CHD. Until
these studies are completed, clinicians will have to rely on
evidence from basic science, epidemiology, and results from
trials in secondary prevention to make recommendations
regarding the use of HRT for the primary prevention of CHD.
The Women’s Health Initiative, which includes a large-scale
randomized trial of HRT, and a similar study in Europe
(WISDOM) were initiated because there was enough evi-
dence to believe there might be a benefit of HRT in primary
prevention, yet enough uncertainty that it was ethical to
randomize half of the participants to placebo.15 Similarly,
there is neither a compelling reason to initiate ERT/HRT in a
woman for the sole purpose of primary CHD prevention nor
a compelling reason to discontinue it if she is doing well with
therapy. The decision to use HRT should be based primarily
on the proven benefits of ERT/HRT on other systems and on
the potential risks of therapy, as well as patient preference.
Are There Adverse Cardiovascular Effects
Associated With ERT/HRT?
One meta-analysis of 22 randomized trials before 1997 that
compared HRT with placebo, no therapy, or vitamin/minerals
in predominantly healthy postmenopausal women showed no
overall cardioprotective effect of therapy.16 There was a
nonsignificant 39% increase in cardiovascular events. Al-
though the 2.89-fold (95% CI 0.34 to 24.8) increase in the
risk of VTE was not significant, it is consistent with other
population-based, nonrandomized studies and with the data
from HERS. Because the data were generated from small-
scale studies examining various HRT preparations, and be-
cause assessment of CVD events categorized as adverse
events may not have been systematic, these results have to be
confirmed in larger, randomized studies.
The Coronary Drug Project, a randomized trial conducted
between 1966 and 1974 in men with documented MI,
compared 2 doses of estrogen (2.5 and 5.0 mg/d) versus
placebo and provided an opportunity to evaluate estrogen for
secondary prevention in men.17 A reanalysis of data from the
Coronary Drug Project showed a significant increase in
primary CHD events at 0 to 4 months (relative hazard 1.58,
95% CI 1.04 to 2.40).18 This early increase in risk in men
paralleled a similar time frame analyzed for the HERS trial,
which showed a nonsignificant 2.3-fold increased risk for
HRT versus placebo (relative hazard 2.29, 95% CI 0.94 to
5.56). Both studies documented an increased risk of throm-
boembolic events and gallbladder disease.
To assess the risk of CVD events in women without
existing CVD who were treated with HRT, the Group Health
Cooperative examined the association of new use of HRT
with risk of first MI in a population-based case-control
study.19 The odds ratio for MI was nonsignificant at 1.39
(95% CI 0.52 to 3.72) among new users of HRT (,6 months)
compared with nonusers. A pattern of significant reduction in
risk with increased time since initiation of therapy was
evident. The odds ratio was 0.66 (95% CI 0.47 to 0.92) for
initiation of therapy .4 years before the index date. A
follow-up study revealed that among women with hyperten-
sion, the risk of MI was increased nearly 11-fold among
women who were current users of HRT and had a prothrom-
bin variant (20210 G to A) compared with a wild-type
genotype.20 This finding suggests that screening for genetic
susceptibility to thrombosis in certain subgroups of women
may provide enhanced assessment of the benefits and risks
of HRT.
The Women’s Health Initiative has informed participants
that among predominantly healthy women randomized to
ERT alone (CEE 0.625 mg/d) or HRT (CEE 0.625 mg/d plus
MPA 2.5 mg/d), there was an early increased risk of cardio-
vascular events compared with women randomized to place-
bo.21 In the first 2 years of the trial, there was the anticipated
excess of VTE but also an excess of MI and stroke that was
not expected (Jacques Rossouw, MD, personal communica-
tion, 2000). The difference between the treatment and pla-
cebo groups appeared to diminish over time, and the trial is
ongoing. The absolute percentage of women who experienced
any of these early CVD events was ,1%.
Data regarding HRT and the primary prevention of stroke
risk have been reviewed recently and are not conclusive.22
The majority of studies have had neutral outcomes, including
the recently analyzed HERS data, which provided no evi-
dence that HRT has a significant effect on the overall risk for
Mosca et al Hormone Replacement Therapy and CVD 501
 by guest on M
arch 29, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 
stroke among postmenopausal women with coronary artery
disease.23 A nonsignificant increase in the risk for fatal stroke
(relative hazard 1.61, 95% CI 0.97 to 3.55) was seen. A recent
report from the Nurses’ Health Study suggested an increased
stroke risk associated with a dose of CEE of $0.625 mg/d
(with or without progestin) but not with lower doses.24,25
Results from the first double-blind, placebo-controlled trial
among postmenopausal women with established cerebrovas-
cular disease, the Women’s Estrogen for Stroke Trial
(WEST), suggested estrogen was not effective for preventing
recurrent stroke or death. In addition, women randomized to
estrogen had a significant increase in the risk for fatal stroke
and more severe neurological impairments after stroke.25
In the HERS trial, the rate of VTE was increased nearly
3-fold in the HRT group compared with placebo.26 Risk for
VTE was increased 5-fold in the first 90 days after MI, even
after adjustment for hospitalization. Because ERT and immo-
bilization may be associated with hypercoagulable states, it
may be prudent to discontinue HRT during hospitalization for
an acute coronary event or to ensure that appropriate mea-
sures for VTE prophylaxis are used during the period of
immobilization, although data are limited. No large-scale
randomized trials with clinical end points have examined the
short-term effect of HRT in acute coronary syndromes or
after revascularization procedures. In a preliminary report
using registry data, ERT use was associated with reduced
in-hospital mortality after MI; however, selection bias cannot
be ruled out to explain the observation.27
Are There Alternatives to HRT?
Selective estrogen-receptor modulators (SERMs) bind to
estrogen receptors with high affinity and exhibit estrogen-
agonist effects in bone and on lipoproteins and estrogen-an-
tagonist effects on the breast and endometrium. Although
SERMs have shown beneficial effects on some surrogate
markers of CVD, it is not known whether this will translate
into a clinical benefit. The Raloxifene Use for The Heart
(RUTH) trial is currently testing the impact of the SERM
raloxifene on cardiovascular end points in .10 000 women.28
Soy phytoestrogens have shown beneficial effects on endo-
thelium-dependent vasodilation and the development of athero-
sclerosis in nonhuman primates,29 but recent data in healthy
postmenopausal women failed to show improvements in li-
poprotein levels or endothelial function after 8 weeks of treat-
ment with isoflavones (80 mg/d).30 Clinical end-point data from
well-conducted trials are not available to make recommenda-
tions concerning use of soy for prevention of CVD.
What Are Accepted Preventive Strategies for
CHD in Postmenopausal Women?
The American Heart Association and the American College
of Cardiology recently published recommendations for the
management of CHD risk factors in women with and without
existing CHD.31 Lifestyle approaches, including smoking
avoidance, proper nutrition, and regular exercise, are indi-
cated in all women. Lipid lowering and blood pressure
control with pharmacotherapy are indicated in women who
do not meet target lipid or blood pressure levels with lifestyle
interventions. For women with CHD, antiplatelet agents or
(when indicated) anticoagulants, b-blockers, and ACE inhib-
itors should also be considered unless there are contraindica-
tions to therapy. Widespread underutilization of established
preventive therapies has been documented in women; these
interventions should be emphasized in clinical practice. A
recent survey by the American Heart Association in 1000
randomly selected women found that 90% of women wanted
to discuss prevention with their doctor but 70% had not.32 In
that study, only 8% of women identified heart disease and
stroke as their greatest health concern, which could impede
preventive efforts. Physicians should focus on educating
women about CVD risk and should uniformly apply proven
CHD risk-reduction therapies with established benefits in
women.
Summary Recommendations for HRT*
and CVD
Secondary Prevention
c HRT should not be initiated for the secondary prevention of
CVD.
c The decision to continue or stop HRT in women with CVD
who have been undergoing long-term HRT should be based
on established noncoronary benefits and risks and patient
preference.
c If a woman develops an acute CVD event or is immobilized
while undergoing HRT, it is prudent to consider discon-
tinuance of the HRT or to consider VTE prophylaxis while
she is hospitalized to minimize risk of VTE associated with
immobilization. Reinstitution of HRT should be based on
established noncoronary benefits and risks, as well as
patient preference.
Primary Prevention
c Firm clinical recommendations for primary prevention
await the results of ongoing randomized clinical trials.
c There are insufficient data to suggest that HRT should be
initiated for the sole purpose of primary prevention of
CVD.
c Initiation and continuation of HRT should be based on
established noncoronary benefits and risks, possible coro-
nary benefits and risks, and patient preference.
*The majority of data available to make clinical recommendations
are based on standard doses of oral CEE/MPA. Evidence is insuffi-
cient to determine whether different preparations, routes of delivery,
doses, or different progestins have a more favorable or more adverse
effect on clinical CVD end points.
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